MAPT and amyloidosis: Both plasma p‐tau217 assays were closely linked to amyloid and tau PET and effectively distinguished AD from other neurodegenerative diseases. Plasma p‐tau217 levels increased with AD severity and were tracked with annual tau PET changes.